XML 161 R101.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations (Details) - Frame Pharmaceuticals B.v.Amsterdam Netherlands
€ / shares in Units, € in Thousands
12 Months Ended
Jun. 08, 2022
EUR (€)
Dec. 31, 2023
EUR (€)
Option
shares
item
Milestone
€ / shares
Jul. 01, 2022
shares
Business Combinations      
Amount of fair value € 32,000    
Net amount of discharging contractual obligations 1,560 € 1,560  
Number of payments in which the total consideration is to be paid | item   3  
Contingent consideration, Number of payments considered | item   2  
Issuance and transfer of shares to former Frame shareholders | shares   810,242  
Value of shares issued to former Frame shareholders   € 11,040  
Closing Share Price | € / shares   € 13.63  
Issuance and transfer of shares as consideration for discharging the contractual obligations for the outstanding advisory agreements | shares   48,254  
Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements   € 658  
Cash payments   585  
Consideration paid in cash for the settlement of the vested employee options   335  
Additional cash consideration   € 250  
Contingent consideration, Percentage of total consideration   50.00%  
Contingent consideration, Number of milestones | Milestone   2  
Number of shares issued upon the achievement of the successful investigational new drug application filing | shares   194,644  
Percentage of consideration transferred upon the achievement of the successful investigational new drug application filing   10.00%  
Value of shares issued upon the achievement of the successful investigational new drug application filing   € 1,831  
Number of shares issued upon successful proof of mechanism in humans | shares   778,575  
Percentage of consideration transferred upon successful proof of mechanism in humans   40.00%  
Value of shares issued upon successful proof of mechanism in humans   € 5,367  
Contingent consideration, fair value   7,198  
Total purchase price € 34,000 € 19,481  
Aggregate consideration in shares | shares   858,496 858,496
Value of aggregate consideration in shares   € 11,697  
Value of shares issued to former Frame shareholders   € 11,697  
Contingent Consideration, Maximum shares issuable | shares   973,236  
RSUs issued to certain former employees | Option   89,655  
Total fair value of the RSU grant   € 1,218  
Number of tranches for vesting of RSUs granted | item   3  
Transactions costs   € 500  
Provisional fair value   6,216  
Signing share price representing 10%   32,000  
Signing share price representing 40%   32,000  
net deferred tax liability   € 20